Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival

Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival

Abstract Background Tumor mutational burden (TMB; the quantity of aberrant nucleotide sequences a given tumor may harbor) has been associated with response to immune checkpoint inhibitor therapy and is gaining broad acceptance as a result. However, TMB harbors intrinsic variability across cancer typ...

Full description

Bibliographic Details
Main Authors: Mary A. Wood, Benjamin R. Weeder, Julianne K. David, Abhinav Nellore, Reid F. Thompson
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Genome Medicine
Subjects:
Tumor mutational burden
TMB
Neoepitopes
Neoepitope burden
Neoantigens
Splice junctions
Online Access:http://link.springer.com/article/10.1186/s13073-020-00729-2

Internet

http://link.springer.com/article/10.1186/s13073-020-00729-2

Similar Items